RAVE June 2024 Abstracts and Posters
678 Patient-reported outcomes for GSK1070806, an anti-IL-18 monoclonal antibody: a phase 1b, randomised, double-blind, parallel-group placebo-controlled study of patients with atopic dermatitis
Parima Ghafoori, PharmD, Lea Fortunato, PhD2 Dharm S. Patel, PhD, Joanne Ellis, PhD, Gabriel Wong, MD, John B. Kelly, MD, PhD, Helen Birch, PhD, Wen-Hung Chen, PhD, Iain Uings, BSc
679 Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
Emma Guttman-Yassky, Ehsanollah Esfandiari, Hirotaka Mano, Takahiro Arai, Kenji Kabashima
680 Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
Matthew J. Zirwas, Mark Boguniewicz, David Rosmarin, Zelma Chiesa Fuxench, Richard B. Warren, Tiago Torres, Marjolein de Bruin-Weller, Zach Dawson, Amber Reck Atwater, Hany Elmaraghy, Evangeline Pierce, Laia Bardolet, Jinglin Zhong, April W. Armstrong
681 Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Ruth Ann Vleugels, Ayman Grada, Emma Yue, Christopher G Bunick, Fabrizio Galimberti, Whitney Krueger
682 Dupilumab demonstrates higher likelihood of maintaining efficacy outcomes compared with lebrikizumab in monotherapy at week 52: results from a placebo-adjusted indirect comparison analysis
Patricia Guyot, Yingxin Xu, Amy Praestgaard, Nick Freemantle, Ana B. Rossi, Brad Shumel, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian
683 Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study
Christopher G. Bunick, Ayman Grada, James Del Rosso, April W. Armstrong, Emma Yue, Whitney Krueger
684 Amlitelimab (an anti-OX40 Ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: Study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY
Linda Stein Gold, Stephan Weidinger, Delphine Staumont-Salle, Saeko Nakajima, Eric L. Simpson, Marjolein de Bruin Weller, Sonya Davey, Kassim Rahawi, Charlotte Bernigaud
685 Onset and maintenance of optimal itch response in adult patients with moderate-to-severe atopic dermatitis treated with dupilumab: post hoc analysis from LIBERTY AD CHRONOS
Sonja Ständer, Gil Yosipovitch, Eric L. Simpson, Brian S. Kim, Kenji Kabashima, Diamant Thaçi, Martin Metz, Zhen Chen, Sandra Hagen, Mike Bastian
686 Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis
Lisa A. Beck, Eric L. Simpson, Michele Ramien, Mark Tang, Joel C. Joyce, Amy Praestgaard, Ana B. Rossi, Drew Clearfield, Annie Zhang
687 Treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis: an observational study
Penny Asbell, Esen K. Akpek, Winston Chamberlain, Zhen Chen, Anna Coleman, Ana B. Rossi, Brad Shumel